A systematic review of cost-effectiveness analyses across the acute kidney injury landscape

References

• Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.
   PubMed Web of Science ®Google Scholar
• Kellum JA, Lameire N, Aspelin P, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012; 2:1–138.
   Google Scholar
• Makris K, Spanou L. Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev. 2016 May;37(2):85–98.
   PubMedGoogle Scholar
• Sawhney S, Marks A, Fluck N, et al. Intermediate and long-term outcomes of survivors of acute kidney injury episodes: A large population-based cohort study. Am J Kidney Dis. 2017 Jan;69(1):18–28.
   PubMed Web of Science ®Google Scholar
• Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017 Apr;13(4):241–257.
   PubMed Web of Science ®Google Scholar
• Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014 Jul 3;371(1):58–66.
   PubMed Web of Science ®Google Scholar
• Li PK T, Burdmann EA, Mehta RL. Acute kidney injury: global health alert. Int J Organ Transplant Med. 2013;4(1):1–8.
   PubMedGoogle Scholar
• Silver SA, Chertow GM. The economic consequences of acute kidney injury. Nephron. 2017;137(4):297–301.
   PubMed Web of Science ®Google Scholar
• United States Renal Data System. 2017 USRDS annual data report: epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of DIabetes and Digestive and Kidney Diseases; 2017.
   Google Scholar
• Dasta JF, Kane-Gill S. Review of the literature on the costs associated with acute kidney injury. J Pharm Pract. 2019 Jun;32(3):292–302.
   PubMed Web of Science ®Google Scholar
• Dasta JF, Kane-Gill SL, Durtschi AJ, et al. Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. Nephrol Dial Transplant. 2008 Jun;23(6):1970–1974.
   PubMed Web of Science ®Google Scholar
• Berns AS. Nephrotoxicity of contrast media. Kidney Int. 1989 Oct;36(4):730–740.
   PubMed Web of Science ®Google Scholar
• Rudnick MR, Goldfarb S, Tumlin J. Contrast-induced nephropathy: is the picture any clearer? Clin J Am Soc Nephrol. 2008 Jan;3(1):261–262.
   PubMed Web of Science ®Google Scholar
• Kilonzo KG, Akrabi HF, Yeates KE. Cost-effectiveness of acute peritoneal dialysis: considerations from Africa. Clin Nephrol. 2020 Supplement-Jan;93(1):72–75.
   PubMed Web of Science ®Google Scholar
• Hocher B. The cost-effectiveness analysis (CEA) is dependent on the quality of the NEPHRIC study. Am Heart J. 2006 Jan;;151(1):e5. author reply e7
   PubMedGoogle Scholar
• Tuon FF, Florencio KL, Rocha JL, et al. Long-term cost-effectiveness of lipid formulations of amphotericin B in the empirical therapy of invasive mycosis in a developing country. Rev Iberoam Micol. 2017 Oct-Dec;;34(4):247–248.
   PubMed Web of Science ®Google Scholar
• Takatori M, Yamaoka M, Nogami S, et al. Online CHDF system: excellent cost-effectiveness for continuous renal replacement therapy with high efficacy and individualization. Contrib Nephrol. 2010;166:173–180.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013 Mar-Apr;16(2):231–250.
   PubMed Web of Science ®Google Scholar
• De Smedt DM, Elseviers MM, Lins RL, et al. Economic evaluation of different treatment modalities in acute kidney injury. Nephrol Dial Transplant. 2012 Nov;27(11):4095–4101.
   PubMed Web of Science ®Google Scholar
• Desai AA, Baras J, Berk BB, et al. Management of acute kidney injury in the intensive care unit: a cost-effectiveness analysis of daily vs alternate-day hemodialysis. Arch Intern Med. 2008 Sep 8;168(16):1761–1767.
   PubMedGoogle Scholar
• Ethgen O, Schneider AG, Bagshaw SM, et al. Economics of dialysis dependence following renal replacement therapy for critically ill acute kidney injury patients. Nephrol Dial Transplant. 2015 Jan;30(1):54–61.
   PubMed Web of Science ®Google Scholar
• Garay OU, Palacios A, Pichon-Riviere A, et al. The cost-effectiveness of continuous versus intermittent renal replacement therapies in acute kidney injury: perspective of the social services for the elderly in Argentina. Value Health Reg Issues. 2019 Dec;20:142–148. .
   PubMedGoogle Scholar
• Klarenbach S, Manns B, Pannu N, et al. Economic evaluation of continuous renal replacement therapy in acute renal failure. Int J Technol Assess Health Care. 2009 Jul;25(3):331–338.
   PubMed Web of Science ®Google Scholar
• Laukkanen A, Emaus L, Pettilä V, et al. Five-year cost-utility analysis of acute renal replacement therapy: a societal perspective. Intensive Care Med. 2013 Mar;39(3):406–413. .
   PubMed Web of Science ®Google Scholar
• Aspelin P, Aubry P, Fransson SG, et al. Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy. Am Heart J. 2005 Feb;149(2):298–303.
   PubMed Web of Science ®Google Scholar
• Chicaíza-Becerra LA, García-Molina M, Gamboa Ó. Cost-effectiveness of iso- versus low-osmolality contrast media in outpatients with high risk of contrast medium-induced nephropathy. Biomedica. 2012 Jun;32(2):182–188. .
   PubMed Web of Science ®Google Scholar
• Javanbakht M, Hemami MR, Mashayekhi A, et al. DyeVert™ PLUS EZ system for preventing contrast-induced acute kidney injury in patients undergoing diagnostic coronary angiography and/or percutaneous coronary intervention: A UK-based cost-utility analysis. Pharmacoecon Open. 2020;4(3):459-472.
   Web of Science ®Google Scholar
• Petrovic S, Bogavac-Stanojevic N, Lakic D, et al. Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. Biochem Med (Zagreb). 2015;25(2):262–271. .
   PubMed Web of Science ®Google Scholar
• Shaw AD, Chalfin DB, Kleintjens J. The economic impact and cost-effectiveness of urinary neutrophil gelatinase-associated lipocalin after cardiac surgery. Clin Ther. 2011 Nov;33(11):1713–1725. .
   PubMed Web of Science ®Google Scholar
• Elseviers MM, Lins RL, Van der Niepen P, et al. Renal replacement therapy is an independent risk factor for mortality in critically ill patients with acute kidney injury. Crit Care. 2010;14(6):R221.
   PubMed Web of Science ®Google Scholar
• Wald R, Shariff SZ, Adhikari NK, et al. The association between renal replacement therapy modality and long-term outcomes among critically ill adults with acute kidney injury: a retrospective cohort study*. Crit Care Med. 2014 Apr;42(4):868–877.
   PubMed Web of Science ®Google Scholar
• Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002 Jan 31;346(5):305–310.
   PubMed Web of Science ®Google Scholar
• Ahlström A, Tallgren M, Peltonen S, et al. Survival and quality of life of patients requiring acute renal replacement therapy. Intensive Care Med. 2005 Sep;31(9):1222–1228.
   PubMed Web of Science ®Google Scholar
• Hoch JS, Dewa CS. A clinician’s guide to correct cost-effectiveness analysis: think incremental not average. Can J Psychiatry. 2008 Apr;53(4):267–274.
   PubMed Web of Science ®Google Scholar
• Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003 Feb 6;348(6):491–499.
   PubMed Web of Science ®Google Scholar
• Gurm HS, Mavromatis K, Bertolet B, et al. Minimizing radiographic contrast administration during coronary angiography using a novel contrast reduction system: A multicenter observational study of the DyeVert™ plus contrast reduction system. Catheter Cardiovasc Interv. 2019 Jun 1;93(7):1228–1235.
   PubMed Web of Science ®Google Scholar
• Peco-Antić A, Ivanišević I, Vulićević I, et al. Biomarkers of acute kidney injury in pediatric cardiac surgery. Clin Biochem. 2013 Sep;46(13–14):1244–1251.
   PubMed Web of Science ®Google Scholar
• Latimer NR. Survival analysis for economic evaluations alongside clinical trials–extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013 Aug;33(6):743–754.
   PubMed Web of Science ®Google Scholar
• Williams C, Lewsey JD, Mackay DF, et al. Estimation of survival probabilities for use in cost-effectiveness analyses: A comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling. Med Decis Making. 2017 May;37(4):427–439.
   PubMed Web of Science ®Google Scholar
• Neumann P, Sanders G, Russell L, et al. Cost-effectiveness in health and medicine. 2nd ed. New York, NY: Oxford University Press; 2016.
   Google Scholar
• Kellum JA, Fuhrman DY. The handwriting is on the wall: there will soon be a drug for AKI. Nat Rev Nephrol. 2019 Feb;15(2):65–66.
   PubMed Web of Science ®Google Scholar